WO2004045621A1 - Process to minimize loss through adhesion to equipment surfaces - Google Patents

Process to minimize loss through adhesion to equipment surfaces Download PDF

Info

Publication number
WO2004045621A1
WO2004045621A1 PCT/SE2003/001760 SE0301760W WO2004045621A1 WO 2004045621 A1 WO2004045621 A1 WO 2004045621A1 SE 0301760 W SE0301760 W SE 0301760W WO 2004045621 A1 WO2004045621 A1 WO 2004045621A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
components
budesonide
adhesion
process according
Prior art date
Application number
PCT/SE2003/001760
Other languages
French (fr)
Inventor
Simon Cawthorne
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20289572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004045621(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MXPA05005088A priority Critical patent/MXPA05005088A/en
Priority to US10/534,377 priority patent/US20060147387A1/en
Priority to EP03811569A priority patent/EP1633369B1/en
Priority to JP2004553343A priority patent/JP2006510614A/en
Priority to AU2003276808A priority patent/AU2003276808B2/en
Priority to DK03811569T priority patent/DK1633369T3/en
Priority to SI200330808T priority patent/SI1633369T1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to NZ539987A priority patent/NZ539987A/en
Priority to BR0316173-0A priority patent/BR0316173A/en
Priority to CA002505486A priority patent/CA2505486A1/en
Priority to DE60313374T priority patent/DE60313374T2/en
Publication of WO2004045621A1 publication Critical patent/WO2004045621A1/en
Priority to NO20052895A priority patent/NO20052895L/en
Priority to CY20071100807T priority patent/CY1106663T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Definitions

  • the present invention relates to a new process for the preparation of combinations of drugs, in particular combinations of inhaled corticosteroids and ⁇ 2 agonists.
  • the first aspect of the invention therefore provides a process to minimise loss of one or more of the components through adhesion to equipment surfaces, which comprises addition of two or more components to a container in a stepwise manner in order to minimise loss of one or more of the components through adhesion to equipment surfaces.
  • the invention also provides a process for adding components to a multicomponent pharmaceutical formulation for inhalation comprising a step wise addition of the components to a container in order to minimize or iradicate losses due to adhesion of component to the container surface.
  • container means any vessel suitable such as a glass or metal vessel used for the preparation of a pharmaceutical formulation such as pilot plant vessels and larger vessels used for pharmaceutical manufacture.
  • This invention particularly applies to formulations where the drug or drugs have a tendency to adhere to the surfaces of the manufacturing equipment in which they are mixed and through which they are dispensed into the container, canister or dosing device.
  • this invention particularly applies to the manufacture of suspension formulations and most preferably to that of drug suspended in a hydrofluoroalkane propellant.
  • Preferred propellants are HFA 134a and HFA 227 and mixtures thereof.
  • the methodology of the production is known in the art and comprises the usual manufacturing equipment for preparation of large quantities of suspension formulation under pressure, for through-the-valve pressure filling of the canisters.
  • the principal could equally apply to equipment of smaller surface area and/or sytems not under pressure, for instance when MDIs are produced under the method of cold fill or where aqueous suspension formulations are being prepared.
  • the drugs of the invention are budesonide and formoterol or a hydrate of a salt thereof, in particular formoterol fumarate dihydrate.
  • the larger component is added first.
  • the budesonide is added prior to the addition of the formoterol fumarate dihydrate.
  • the process of controlled addition significantly reduces the Formoterol normally lost during manufacture such that the manufacturing overages are significantly reduced, or preferably, not required at all.
  • the molar ratio of the budesonide to the formoterol fumarate dihydrate is from 2500:1 to 1:1.
  • the molar ratio of the budesonide to the formoterol fumarate dihydrate is preferably from 555:1 to 1:1, and more preferably from 150:1 to 1:1.
  • the molar ratio of the budesonide to the formoterol fumarate dihydrate is even more preferably from 133:1 to 6:1.
  • the molar ratio of the budesonide to the formoterol fumarate dihydrate is most preferably 50: 1 to 6: 1
  • ratios in weight/weight terms are: Budesonide to Formoterol of 200:1 to 1:1, or more preferably 40:1 to 10:1.
  • the invention provides a pharmaceutical formulation prepared according to the above process and the use of such a formulation in therapy in particular the treatment and prophylaxis of respiratory disorders such as asthma and COPD.
  • the invention also provides a method of treating asthma or COPD, which comprised administering to a patient in need of such treatment a formulation as defined and prepared above.
  • the formulations prepared according to the invention optionally comprise one or more pharmaceutically acceptable suspending agents, valve lubricants, flavourings, bulking agents, sweetners or cosolvents.
  • the formulations are preferably in the form of a micronised powder for inhalation suspended in a hydrofluoroalkane propellant, wherein the particles of the pharmaceutically active ingredients have a mass median diameter of less than 10 ⁇ m.
  • the amount of the active ingredients in the resulting pMDI's was assayed and compared to theoretical.
  • the resulting API (active pharmaceutical ingredient) concentration was determined by Total Can Assay. The differences seen cannot be attributed to error in assay results due to analytical variation (Assay RSD 0.9%)
  • FFD Formoterol fumurate dihydrate
  • BUD budesonide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Printed Wiring (AREA)
  • Laminated Bodies (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)

Abstract

The invention relates to a new process for preparing combination formulations of inhaled glucocorticoids and beta 2-agonists, e.g. budesonide in combination with formoterol. The process aims at minimizing adhesion of one or more of the ingredients to equipment surfaces by adding the ingredients to a container in a stepwise manner.

Description

Process to minimize loss through adhesion to equipment surfaces
The present invention relates to a new process for the preparation of combinations of drugs, in particular combinations of inhaled corticosteroids and β2 agonists.
It is known that some pharmaceutical compounds suitable for administration via pressurised metered dose inhalers (pMDI's) have a tendency to adhere to the container surface. This problem is particularly noticeable with HFA formulations and there are patent applications, which detail the problem and possible solutions. For example, EP642992, WO96/32099 and US6253762 deal with adhesion on the walls of the MDI canister, but the term container used above is not limited to only the canister.
Less well known is that fact that the problem also applies to the surfaces of the manufacturing vessel and filling equipment. This makes filling of the metered dose inhaler container and subsequent dosing from those containers, less uniform. The problem has traditionally been overcome by adding an overage to the formulation, i.e. adding more of one or more of the ingredients than is theoretically required. However the effect cannot always be consistent enough for the overage method to alleviate the problem and as the extent of adhesion is not constant from batch to batch, much validation work has to be carried out to define the range of permitted overage for that product which will most likely result in an acceptable product in terms of reliable and consistent drug content for each dose. Details of such an investigation can be found in the proceedings of Drug delivery to the Lungs 1997 pgs47-50 "Production Scale Optimisation of the Manufacturing Process or a HFA 134A Metered Dose Inhaler Containing Both Salmeterol and Fluticasone Propionate " Duquemin et al. One of the parameters to be optimised was the drug overage I.e the amount of extra drug added to compensate for the loss of drug during the production process.
In the case of expensive drug compound, drug overages can add significantly to the cost of the final product. Also this is not nessessarily an easy solution as each active has to be optimised in combination products and the adhesion as mentioned above can vary from vessel to vessel and batch to batch. This can result in unacceptable rate of batch failure on dose content from the MDIs produced
Another factor is that the permitted overages are limited by the regulatory bodies to less than 10% of actives, which for a dilute product in a large production vessel may not be enough to cover losses. It was found that if the actives were added to the mix in a predetermined and precise stepwise manner, one active added first in preference to the other, then no overages were necessary. This is a significant and suprising finding.
It would be assumed that as part of the mixing process, over time, the adhesion of each drug would be in proportion to a) its content in the mix and b) the area of the vessel. This has not turned out to be the case as no overage is required even in a large production vessel.
The first aspect of the invention therefore provides a process to minimise loss of one or more of the components through adhesion to equipment surfaces, which comprises addition of two or more components to a container in a stepwise manner in order to minimise loss of one or more of the components through adhesion to equipment surfaces.
The invention also provides a process for adding components to a multicomponent pharmaceutical formulation for inhalation comprising a step wise addition of the components to a container in order to minimize or iradicate losses due to adhesion of component to the container surface. The term "container" means any vessel suitable such as a glass or metal vessel used for the preparation of a pharmaceutical formulation such as pilot plant vessels and larger vessels used for pharmaceutical manufacture.
This invention particularly applies to formulations where the drug or drugs have a tendency to adhere to the surfaces of the manufacturing equipment in which they are mixed and through which they are dispensed into the container, canister or dosing device.
Also this invention particularly applies to the manufacture of suspension formulations and most preferably to that of drug suspended in a hydrofluoroalkane propellant. Preferred propellants are HFA 134a and HFA 227 and mixtures thereof.
The methodology of the production is known in the art and comprises the usual manufacturing equipment for preparation of large quantities of suspension formulation under pressure, for through-the-valve pressure filling of the canisters. However the principal could equally apply to equipment of smaller surface area and/or sytems not under pressure, for instance when MDIs are produced under the method of cold fill or where aqueous suspension formulations are being prepared. Preferably the drugs of the invention are budesonide and formoterol or a hydrate of a salt thereof, in particular formoterol fumarate dihydrate.
Essentially, the larger component is added first. Essentially, therefore, the budesonide is added prior to the addition of the formoterol fumarate dihydrate.
The process of controlled addition significantly reduces the Formoterol normally lost during manufacture such that the manufacturing overages are significantly reduced, or preferably, not required at all.
Suitably the molar ratio of the budesonide to the formoterol fumarate dihydrate is from 2500:1 to 1:1.
The molar ratio of the budesonide to the formoterol fumarate dihydrate is preferably from 555:1 to 1:1, and more preferably from 150:1 to 1:1. The molar ratio of the budesonide to the formoterol fumarate dihydrate is even more preferably from 133:1 to 6:1. The molar ratio of the budesonide to the formoterol fumarate dihydrate is most preferably 50: 1 to 6: 1
In terms of dosing ratios for a combination product producted by this method, ratios in weight/weight terms are: Budesonide to Formoterol of 200:1 to 1:1, or more preferably 40:1 to 10:1.
In a further aspect the invention provides a pharmaceutical formulation prepared according to the above process and the use of such a formulation in therapy in particular the treatment and prophylaxis of respiratory disorders such as asthma and COPD.
The invention also provides a method of treating asthma or COPD, which comprised administering to a patient in need of such treatment a formulation as defined and prepared above.
The formulations prepared according to the invention optionally comprise one or more pharmaceutically acceptable suspending agents, valve lubricants, flavourings, bulking agents, sweetners or cosolvents. The formulations are preferably in the form of a micronised powder for inhalation suspended in a hydrofluoroalkane propellant, wherein the particles of the pharmaceutically active ingredients have a mass median diameter of less than 10 μm.
EXPERIMENTAL DETAILS
The invention is illustrated by the following examples.
The examples shown below in Table 1 are of nine batches produced at a commercial manufacturing site
The amount of the active ingredients in the resulting pMDI's was assayed and compared to theoretical. The resulting API (active pharmaceutical ingredient) concentration was determined by Total Can Assay. The differences seen cannot be attributed to error in assay results due to analytical variation (Assay RSD 0.9%)
The results for each batch show the overage of Formoterol added, the theoretical amount expected if no loss occurs, the resulting assay figure and which API was added first.
TABLE 1
Figure imgf000005_0001
FFD = Formoterol fumurate dihydrate BUD = budesonide
Conclusion
The addition of Budesonide prior to the addition of Formoterol
1 reduces the amount of Formoterol that is lost during manufacture
2 such that the manufacturing overages are significantly reduced or negated entirely
3 gives advantage over random addition in that this method makes the outcome of the final API concentration more consistent and well within manufacturing allowances (+/- 5%)
4 reduces the likelihood of batch failure
5 thereby reducing overall costs.

Claims

Claims
1. A process to minimise loss of one or more of the components through adhesion to equipment surfaces, which comprises addition of two or more components to a container. in a stepwise manner.
2. A process for adding components to a multicomponent pharmaceutical formulation for inhalation comprising a step wise addition of the components to a container in order to minimize or iradicate losses due to adhesion of component to the container surface.
3. A process according to claim 1 or 2 in which the component of largest mass is added first.
4. A process according to claim 2 or 3 in which the formulation components are active drug substances.
5. A process according to any one of claims 2 to 4 in which the formulation is for a pressurized metered dose inhaler.
6. A process according to claim 4 or 5 in which the active drug substances are budesonide and formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.
7. A process according to any one of claims 4 to 6 in which the active drug substances are budesonide and formoterol fumarate dihydrate.
8. A process according to claim 7 in which the molar ratio of the budesonide to the formoterol fumarate dihydrate is from 2500:1 to 1:1.
9. A pharmaceutical formulation prepared according to the process defined in any one of claims 2 to 8.
10. A formulation according to claim 9 which is in the form of a suspension.
11. A formulation according to claim 10 in which the drugs are suspended in one or more HFA propellants.
12. A formulation according to claim 11 in which the HFA propellants are HFA 134a or HFA 227 or a mixture thereof.
13. Use of a formulation according to any one of claims 9 to 12 for the treatment or prophylaxis of asthma or COPD.
14. A method of treating asthma or COPD which comprised administering to a patient in need of such treatment a formulation according to any one of claims 9 to 12.
PCT/SE2003/001760 2002-11-15 2003-11-13 Process to minimize loss through adhesion to equipment surfaces WO2004045621A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE60313374T DE60313374T2 (en) 2002-11-15 2003-11-13 METHOD FOR MINIMIZING LOSSES THROUGH ADHESION ON DEVICE SURFACES
SI200330808T SI1633369T1 (en) 2002-11-15 2003-11-13 Process to minimize loss through adhesion to equipment surfaces
EP03811569A EP1633369B1 (en) 2002-11-15 2003-11-13 Process to minimize loss through adhesion to equipment surfaces
JP2004553343A JP2006510614A (en) 2002-11-15 2003-11-13 Method for minimizing losses due to adhesion to equipment surfaces
AU2003276808A AU2003276808B2 (en) 2002-11-15 2003-11-13 Process to minimize loss through adhesion to equipment surfaces
DK03811569T DK1633369T3 (en) 2002-11-15 2003-11-13 Method of minimizing loss of adhesion to equipment surfaces
NZ539987A NZ539987A (en) 2002-11-15 2003-11-13 Process to minimize loss through adhesion to equipment surfaces
MXPA05005088A MXPA05005088A (en) 2002-11-15 2003-11-13 Process to minimize loss through adhesion to equipment surfaces.
US10/534,377 US20060147387A1 (en) 2002-11-15 2003-11-13 Process to minimize loss through adhesion to equipment surfaces
BR0316173-0A BR0316173A (en) 2002-11-15 2003-11-13 Process to minimize equipment surface adhesion losses
CA002505486A CA2505486A1 (en) 2002-11-15 2003-11-13 Process to minimize loss through adhesion to equipment surfaces
NO20052895A NO20052895L (en) 2002-11-15 2005-06-14 Method of minimizing adhesion losses to equipment surfaces
CY20071100807T CY1106663T1 (en) 2002-11-15 2007-06-20 PROCEDURE TO MINIMIZE LOSS DUE TO ADHESION TO DEVICE SURFACES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0203376A SE0203376D0 (en) 2002-11-15 2002-11-15 New process
SE0203376-9 2002-11-15

Publications (1)

Publication Number Publication Date
WO2004045621A1 true WO2004045621A1 (en) 2004-06-03

Family

ID=20289572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2003/001760 WO2004045621A1 (en) 2002-11-15 2003-11-13 Process to minimize loss through adhesion to equipment surfaces

Country Status (21)

Country Link
US (1) US20060147387A1 (en)
EP (1) EP1633369B1 (en)
JP (1) JP2006510614A (en)
KR (1) KR20050086622A (en)
CN (1) CN1711093A (en)
AT (1) ATE359795T1 (en)
AU (1) AU2003276808B2 (en)
BR (1) BR0316173A (en)
CA (1) CA2505486A1 (en)
CY (1) CY1106663T1 (en)
DE (1) DE60313374T2 (en)
DK (1) DK1633369T3 (en)
ES (1) ES2285269T3 (en)
MX (1) MXPA05005088A (en)
NO (1) NO20052895L (en)
NZ (1) NZ539987A (en)
PT (1) PT1633369E (en)
SE (1) SE0203376D0 (en)
SI (1) SI1633369T1 (en)
WO (1) WO2004045621A1 (en)
ZA (1) ZA200503804B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US9808423B2 (en) 2004-10-12 2017-11-07 Generics [Uk] Limited Preparation of suspension aerosol formulations

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
TWI399202B (en) * 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011773A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
WO2000053188A1 (en) * 1999-03-09 2000-09-14 Astrazeneca Ab New combination of r,r-formoterol and budesonide in a pharmaceutical composition useful for treating respiratory disorders, such as asthma, rhinitis and copd
WO2001078737A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and budesonide
WO2002003958A1 (en) * 2000-07-11 2002-01-17 Astrazeneca Ab Novel aerosol formulation containing a polar fluorinated molecule

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219899B (en) * 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Metered dose inhaler
DK1131059T3 (en) * 1998-11-13 2003-06-30 Jago Res Ag Dry powder for inhalation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011773A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US5972919A (en) * 1991-12-18 1999-10-26 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
WO2000053188A1 (en) * 1999-03-09 2000-09-14 Astrazeneca Ab New combination of r,r-formoterol and budesonide in a pharmaceutical composition useful for treating respiratory disorders, such as asthma, rhinitis and copd
WO2001078737A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and budesonide
WO2002003958A1 (en) * 2000-07-11 2002-01-17 Astrazeneca Ab Novel aerosol formulation containing a polar fluorinated molecule

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US9808423B2 (en) 2004-10-12 2017-11-07 Generics [Uk] Limited Preparation of suspension aerosol formulations

Also Published As

Publication number Publication date
BR0316173A (en) 2005-09-27
SI1633369T1 (en) 2007-08-31
EP1633369A1 (en) 2006-03-15
ZA200503804B (en) 2006-09-27
CY1106663T1 (en) 2012-05-23
NO20052895D0 (en) 2005-06-14
JP2006510614A (en) 2006-03-30
PT1633369E (en) 2007-07-27
NO20052895L (en) 2005-06-14
SE0203376D0 (en) 2002-11-15
AU2003276808B2 (en) 2006-07-06
DK1633369T3 (en) 2007-07-16
EP1633369B1 (en) 2007-04-18
AU2003276808A1 (en) 2004-06-15
MXPA05005088A (en) 2005-07-01
CN1711093A (en) 2005-12-21
CA2505486A1 (en) 2004-06-03
US20060147387A1 (en) 2006-07-06
ATE359795T1 (en) 2007-05-15
DE60313374D1 (en) 2007-05-31
DE60313374T2 (en) 2007-12-27
NZ539987A (en) 2006-11-30
ES2285269T3 (en) 2007-11-16
KR20050086622A (en) 2005-08-30

Similar Documents

Publication Publication Date Title
AU749636B2 (en) A medicinal aerosol formulation
JP5170789B2 (en) Pharmaceutical composition for the treatment of asthma
US5603918A (en) Aerosol composition of a salt of ipratropium and a salt of albuterol
EP1545634B1 (en) Method of preparing dry powder inhalation compositions
EP1670432B1 (en) Aerosol formulations comprising formoterol fumarate dihydrate, a propellant, ethanol and optionally a steroid, where the formoterol fumarate dihydrate has a water content of 4.8-4.28% by weight.
US20090264389A1 (en) Method of preparing dry powder inhalation compositions
JP2006312649A (en) Pharmaceutical composition
JP2019182878A (en) Improved pharmaceutical aerosol formulation
AU719079B2 (en) Chlorofluorocarbon-free mometasone furoate aerosol formulations
ZA200503804B (en) Process to minimize loss through adhesion to equipment surfaces
CN110840864B (en) Beta 2 receptor agonist inhalation aerosol and product containing same
EP1785156B1 (en) Metered dose inhaler containing an aerosol suspension formulation
WO2002015883A1 (en) A method of stabilizing a dry powder pharmaceutical formulation
MXPA01005716A (en) A medicinal aerosol formulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003811569

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 168412

Country of ref document: IL

Ref document number: 2003276808

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006147387

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2505486

Country of ref document: CA

Ref document number: 10534377

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005/03804

Country of ref document: ZA

Ref document number: 200503804

Country of ref document: ZA

Ref document number: 539987

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/005088

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057008624

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004553343

Country of ref document: JP

Ref document number: 20038A33197

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057008624

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0316173

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 2003811569

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10534377

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003811569

Country of ref document: EP